Lucid Group Appoints Former Pfizer R&D Leader Rod MacKenzie, CMG, PhD, as Board Chair to Drive Next Phase of Global Growth and Innovation
March 18, 2026 |
Appointment marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
Lucid’s US Medical Affairs division unveils new proprietary insights tools to expand advisory capabilities.
LONDON & PHILADELPHIA, March 18, 2026 – Lucid Group, a global leader in healthcare communications and commercialisation, today announced that Rod MacKenzie, CMG, PhD, former Executive Vice President and Chief Development Officer at Pfizer, has been appointed as the new Chair of the Lucid Group Board of Directors. Dr MacKenzie will succeed Andy Black, who retired from the Board following the end of his term.
This appointment reflects a shared mission with Lucid Group to transform lives by ensuring innovative medicine doesn’t stop at approval but reaches the patients who need it most. His leadership marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
“Dr MacKenzie’s career is defined by his dedication to patient outcomes and a deep understanding that breakthrough science only matters when translated into action,” said Rick Sannem, CEO of Lucid Group. “His arrival supports our shared vision that we don’t just help clients talk about their science, we uncover the defining insights that shape behaviour so life-changing medicines find their rightful place in the market.”
Dr MacKenzie spent 34 years at Pfizer, where he led the Global Product Development division and oversaw 6,000 professionals dedicated to advancing innovative medicines and vaccines. He played a critical role in the development of both the Pfizer-BioNTech COVID-19 vaccine and antiviral, Paxlovid, in addition to serving on Pfizer’s Executive Leadership Team from 2016 to 2022. In recognition of his contributions to public health during the pandemic, he was appointed Companion of the Order of St Michael and St George by Queen Elizabeth II in 2022.
“Inventing and developing innovative medicines takes great science and execution. But translating that science into improved patient outcomes in clinical practice requires real strategic discipline,” said Dr MacKenzie. “Even brilliant science can struggle to break through, so innovative companies need a strategic partner like Lucid, whose integrated approach to solving complex challenges delivers changes in behaviours that successfully overcome treatment barriers. Lucid’s cre
ativity and unique data synthesis capabilities really stand out in the marketplace. I am thrilled to join the Lucid Board and share Lucid’s deep commitment to transforming lives across the globe.”
In addition to Dr MacKenzie’s appointment, Lucid’s US Medical Affairs division is unveiling new proprietary insights tools to expand its advisory capabilities at the Medical Affairs Professional Society (MAPS) conference in Denver from 22-25 March:
- Influence Amplifier™ – Closes the gap between communication and behaviour change by combining real-time behavioural insights, precision targeting, and adaptive analytics to expand peer-to-peer communication relevance and audience priorities.
- Impact Validator™ – Pinpoints precisely where efforts drive change through a five-step framework spanning clinical gaps and audience priorities, tailored interventions, omnichannel engagement, performance data, and adaptive refinement.
Together, these tools magnify and document scientific impact while delivering Precision Engagement™, a repeatable, self‑optimising cycle that continuously strengthens scientific influence, impact, and patient outcomes over time.
To demonstrate how Lucid Medical is enabling Medical Affairs teams to be strategic catalysts for change, it is offering free, 30-minute Impact Calibration™ sessions designed to map Medical Affairs teams’ current influence and spotlight opportunities for measurable growth.
About Lucid Group
Lucid Group, a global leader in healthcare communications and commercialisation, is driven by a mission to transform lives by bridging the gap between scientific discovery and patient impact. For life sciences organisations navigating their highest-stakes decisions, Lucid doesn’t just communicate science but ensures clients leave a lasting impact on the market and the patients they serve. Lucid brings together experts across Strategy Consulting, Scientific and Medical Communications, and Commercial Communications, fusing scientific rigour, strategic foresight, commercial ingenuity, creative storytelling, and deep human insight into an integrated force, powered by real-world evidence. This unique approach allows Lucid to uncover the ‘Lucid Truth’— the deep-seated insight that governs stakeholder behaviour and anchors bold, behaviour-changing ideas, executed at key moments and accelerated by AI and technology. To learn more about Lucid Group, visit www.wearelucidgroup.com and LinkedIn.
Media Contacts:
Chris Dougherty
CDougherty@reboundb2b.com
Elyse Cole
media@wearelucidgroup.com
This content was provided by Lucid Group Communications Limited
Company Details
Latest Content from Lucid Group Communications Limited
A magic milestone: Katherine’s 10-year workiversary
Katherine Duxbury recently celebrated the momentous and magical milestone of 10 years with Lucid Group – congratulations! Surprise virtual celebrations have been had and, while they were no replacement for...
Lucid Group – Let’s Start Talking
We can all help to transform the lives of those we touch by taking the time to talk and listen to one another. The power of conversation, sharing thoughts, worries...
My Journey Into MedComms #LucidLife
In NetworkPharma’s latest career guide for wannabe account managers, Tessa Rowland, Senior Account Executive, discusses her journey into the varied and fast-paced world of medical communications.
Lucid Group bolster its talent with a further twelve new starters for 2021
As if welcoming eight new graduates was not enough to bring some excitement to the start of the new year, Lucid Group has also welcomed a further twelve new employees...
The Lucid Group Futures Academy welcomes its 2021 cohort
This week Lucid welcomed its newest cohort of graduates onto the 2021 Futures Academy programme. The programme provides graduates with a 12-month structured medical writing training programme. It’s a chance...
Our People and their Growth are at the heart of #LucidLife
2020 has been a year like no other, in more ways than one. We wanted to shine a light on the good and great of 2020 and reflect on far...
Advance Outcomes named of the most innovative strategies of 2020 by PM360
PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named Lucid Group’s pioneering behaviour-change methodology, Advance OutcomesTM, as one of...
Lucid Group Evolve and Simplify its Brand Architecture
The current pandemic has forced many industries to find new ways of working. Within medical communications (medcomms), this has involved pivoting quickly towards a digital-first approach in order to optimise...
Laurence Bannister joins Lucid Group as its new Chief Commercial Officer
Laurence brings a track record of success from 22 years’ experience in pharmaceuticals/healthcare – across affiliate, regional and global commercial roles – with the last 9 years being at STEM...
A Lucid Group Thirsty Thursday: change management and self-efficacy
Last week, Lucid Group were lucky enough to have Richard Nugent, Founder and Managing Director of TwentyOne Leadership, present a session on change management and self-efficacy. Richard often works with...